Fabio Dardi
Overview
Explore the profile of Fabio Dardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209472
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters...
2.
Dardi F, Guarino D, Ballerini A, Bertozzi R, Donato F, Cennerazzo F, et al.
ERJ Open Res
. 2024 Aug;
10(4).
PMID: 39104950
Background: Haemodynamic variables like right atrial pressure (RAP), cardiac index (CI), stroke volume index (SVI) and mixed venous oxygen saturation ( ) predict survival in patients with pulmonary arterial hypertension...
3.
Dardi F, Rotunno M, Guarino D, Suarez S, Niro F, Loforte A, et al.
Int J Cardiol
. 2023 Sep;
391:131333.
PMID: 37673403
Background: Pulmonary endarterectomy (PEA) has been the most effective therapy for chronic thromboembolic pulmonary hypertension (CTEPH). However, there is a substantial proportion of patients deemed not operable in whom other...
4.
Dardi F, Guarino D, Cennerazzo F, Ballerini A, Magnani I, Bertozzi R, et al.
J Clin Med
. 2023 May;
12(10).
PMID: 37240531
Background: Pulmonary arterial hypertension (PAH) may complicate both portal hypertension (Po-PAH) and HIV infection (HIV-PAH). These two conditions, however, frequently coexist in the same patient (HIV/Po-PAH). We evaluated clinical, functional,...
5.
Palazzini M, Dardi F, Magnani I, Guarino D, Galie N, Manes A
Eur Heart J Suppl
. 2023 Apr;
25(Suppl B):B90-B94.
PMID: 37091640
The combination of an initial clinical approach aimed at evaluating the early risk of mortality with subsequent diagnostic and therapeutic approaches articulated on the overall patient's profile is recommended in...
6.
Manes A, Dardi F, Galie N, Palazzini M
G Ital Cardiol (Rome)
. 2023 Feb;
24(3):161-165.
PMID: 36853150
No abstract available.
7.
Martin-Suarez S, Gliozzi G, Cavalli G, Orioli V, Loforte A, Pastore S, et al.
J Clin Med
. 2022 Aug;
11(15).
PMID: 35955972
Background: Pulmonary endarterectomy (PEA) is the gold standard therapy for chronic thromboembolic pulmonary hypertension (CTEPH). Traditionally, pulmonary vascular resistance (PVR) represents the main prognostic factor after surgery. The pulmonary artery...
8.
Dardi F, Manes A, Guarino D, Suarez S, Loforte A, Rotunno M, et al.
Ann Cardiothorac Surg
. 2022 Apr;
11(2):172-174.
PMID: 35433360
No abstract available.
9.
Palazzini M, Saia F, Taglieri N, Guarino D, Rotunno M, Gali N, et al.
Ann Cardiothorac Surg
. 2022 Apr;
11(2):192-194.
PMID: 35433357
No abstract available.
10.
Martin-Suarez S, Loforte A, Cavalli G, Gliozzi G, Botta L, Mariani C, et al.
Ann Cardiothorac Surg
. 2022 Apr;
11(2):120-127.
PMID: 35433353
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease with a very complex pathophysiology differing from other causes of pulmonary hypertension (PH). It is an infrequent consequence of acute pulmonary...